EFFICACY AND SAFETY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA: 24-MONTH INTERIM ANALYSIS OF THE PHASE 3 ENVISION RANDOMIZED CLINICAL TRIAL

Herbert L. Bonkovsky  ¹     Paolo Ventura  ²     Laurent Gouya  ³     Paula Aguilera Peiró  ⁴     D. Montgomery Bissell  ⁵     Penelope E. Stein  ⁶     Manisha Balwani  ⁷     D. Karl E. Anderson  ⁸     Charles Parker  ⁹     David J. Kuter  ¹⁰     Susana Monroy  ¹¹     Jeeyoung Oh  ¹²     Bruce Ritchie  ¹³     Zhaowei Hua  ¹⁴     Eliane Sardh  ¹⁵     John Ko     Marianne T Sweetser    
¹ Wake Forest University/NC Baptist Medical Center, Winston-Salem, United States
² University of Modena and Reggio Emilia, Modena, Italy
³ Centre Français des Porphyries, Paris, France
⁴ Hospital Clinic Barcelona, Barcelona, Spain
⁵ University of California, San Francisco, United States
⁶ King’s College Hospital, London, United Kingdom
⁷ Icahn School of Medicine at Mt. Sinai, New York, United States
⁸ University of Texas Medical Branch, Galveston, United States
⁹ University of Utah, Salt Lake City, United States
¹⁰ Massachusetts General Hospital, Boston, United States
¹¹ Instituto Nacional de Pediatría de Mexico, Mexico City, Mexico
¹² Konkuk University Medical Center, Seoul, Korea, Republic of
¹³ University of Alberta Hospital, Edmonton, Canada
¹⁴ Alnylam Pharmaceuticals, Cambridge, United States
¹⁵ Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Topic
Digestive Oncology, Hepatobiliary

Session
Clinical hepatology: Evolving issues

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)